<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	
	>
<channel>
	<title>
	Commenti a: Tumori, Aifa approva immunoterapico tislelizumab in cancro a esofago, stomaco e polmone BeOne, &#8216;migliora sopravvivenza in 3 neoplasie spesso diagnosticate in stadio avanzato&#8217;	</title>
	<atom:link href="https://www.lafrecciaweb.it/2026/05/12/tumori-aifa-approva-immunoterapico-tislelizumab-in-cancro-a-esofago-stomaco-e-polmone-beone-migliora-sopravvivenza-in-3-neoplasie-spesso-diagnosticate-in-stadio-avanzato/feed/" rel="self" type="application/rss+xml" />
	<link>https://www.lafrecciaweb.it/2026/05/12/tumori-aifa-approva-immunoterapico-tislelizumab-in-cancro-a-esofago-stomaco-e-polmone-beone-migliora-sopravvivenza-in-3-neoplasie-spesso-diagnosticate-in-stadio-avanzato/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=tumori-aifa-approva-immunoterapico-tislelizumab-in-cancro-a-esofago-stomaco-e-polmone-beone-migliora-sopravvivenza-in-3-neoplasie-spesso-diagnosticate-in-stadio-avanzato</link>
	<description>la velocità dell&#039;informazione</description>
	<lastBuildDate>Tue, 12 May 2026 13:43:00 +0000</lastBuildDate>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.9.4</generator>
</channel>
</rss>
